Clinical Trial Update: Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating Apolizumab in patients with relapsed or refractory chronic lymphocytic leukemia or s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Apolizumab (apolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED